COOPERATION

M€ in open calls for proposals for a total Budget of 32.413 M€.
Grants for collaborative R&D Projects involving more than 2 independent entities established in 2 or more EU Member or Associated States, for the development of innovative products, services or processes.

Need funding for your R&D project?


  GRANTS FOR INFECTIOUS DISEASES
JTI-IMI-Call10-1 Immunological Assay Standardisation and Development for use in Assessments of Correlates Of Protection for Influenza Vaccines CALL CLOSED
The long-term goal of this Call is to improve and standardise the existing immunological assays and to develop new assays to better evaluate influenza vaccines. To this end, the overall objectives of this proposed project are to generate validated...
JTI-IMI-Call8-1 Conduct of clinical studies suporting the development of Medi4893, a monoclonal antibody targetings antibody targeting staphylococcus aureus alpha toxin CALL CLOSED
This topic is part of the topic 1 “Innovative trial design and clinical drug development” of the NewDrugs4BadBugs (ND4BB) Programme which, in turn, is a core element of the “Action plan against the rising threats from Antimicrobial Resistance”...
JTI-IMI-Call8-2 Discovery and development of new drugs combatting gram-negative infections CALL CLOSED
Objetives:The ND4BB project ‘Discovery and development of new drugs combatting Gram–negative infections’ will seek to:1) Provide a unique platform to foster collaboration and exchange between private and public partners;2) Establish a vibrant...
JTI-IMI-Call9-3 Driving re-investment in R&D and responsible use of antibiotics CALL CLOSED
This is topic 4 of the NewDrugs4BadBugs (ND4BB) Programme which, in turn, is a core element of the "Action plan against the rising threats from Antimicrobial Resistance" of the EC and it's included in IMI under the theme "Combatting Antimicrobial...
JTI-IMI-Call9-4 Clinical development of antibacterial agents for Gramnegative antibiotic resistant pathogens CALL CLOSED
This is topic 5 of the NewDrugs4BadBugs (ND4BB) Programme which, in turn, is a core element of the "Action plan against the rising threats from Antimicrobial Resistance" of the EC and it's included in IMI under the theme "Combatting Antimicrobial...
IMI will not seek to duplicate other European research programmes. Potential future IMI programmes may be focused more into developing a greater understanding of the immune status of the host (for example, a human pathogen immune project examining translatable animal models, profiling immune cells, understanding host responses among others) and antimicrobial resistance.